Table 1.

Cost-effectiveness results of biannual HCC surveillance in CHB patients with virological remission

Surveillance age group			compensated cirrhosis					advanced fibrosis (non-cirrhotic)
			Costs per patient ($)	QALYs gained per patient	ICERs vs. no surveillance (US$/QALY)	ICER vs. next screening strategy (US$/QALY)		Costs per patient ($)	QALYs gained per patient	ICERs vs. no surveillance (US$/QALY)	ICER vs. next screening strategy (US$/QALY)
No surveillance			86,161	11.533	/	/		6,011	14.820	/	/
Surveillance (Biannual)
	Start age	Stop age
	40	50	92,711	11.597	102,472	102,472		7,467	14.897	18,900	18,900
		55	99,077	11.740	62,512	44,613		8,121	15.009	11,171	5,846
		60	106,303	11.845	64,625	68,779		9,492	15.123	11,501	12,049
		65	115,324	12.027	59,120	49,673		10,546	15.344	8,654	4,760
		70	119,492	12.143	54,652	35,749		11,527	15.419	9,215	13,161
		75	123,954	12.212	55,690	64,894		12,457	15.490	9,616	12,970
	45	55	96,490	11.739	50,146	50,146		7,800	14.964	12,461	12,461
		60	103,062	11.832	56,536	70,694		9,113	15.051	13,418	14,987
		65	112,072	12.017	53,571	48,773		10,161	15.275	9,128	4,691
		70	116,071	12.133	49,855	34,397		11,149	15.351	9,689	13,063
		75	120,523	12.202	51,358	64,403		12,074	15.422	10,070	12,882
	50	60	102,844	11.863	50,661	50,661		9,636	15.089	13,473	13,473
		65	112,030	12.016	53,636	60,039		10,683	15.274	10,296	5,667
		70	115,576	12.135	48,876	29,668		11,726	15.371	10,378	10,764
		75	119,840	12.201	50,442	64,758		12,447	15.429	10,578	12,484
	55	65	101,671	11.846	49,632	49,632		9,236	15.167	9,313	9,313
		70	106,223	11.925	51,236	57,573		10,309	15.231	10,462	16,628
		75	110,585	11.996	52,782	61,289		10,888	15.304	10,081	7,937
	60	70	100,985	11.785	58,964	58,964		8,725	15.116	9,173	9,173
		75	104,049	11.841	58,149	54,505		9,361	15.167	9,674	12,607
	65	75	94,813	11.708	49,429	49,429		8,076	14.970	13,751	13,751

CHB, chronic hepatitis B; HCC, hepatocellular carcinoma; QALY, quality-adjusted life years; ICER, incremental cost-effectiveness ratio